BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1682 related articles for article (PubMed ID: 17199435)

  • 1. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship among thyrotropin (TSH), thyroid stimulating immunoglobulins, and results of triiodothyronine (T3) suppression test in patients with Graves' disease.
    Horimoto M; Nishikawa M; Uno C; Yoshikawa N; Taniguchi N; Inada M
    Endocrinol Jpn; 1988 Dec; 35(6):841-8. PubMed ID: 2471633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease.
    Noh J; Hamada N; Saito H; Oyanagi H; Ishikawa N; Momotani N; Ito K; Morii H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):107-13. PubMed ID: 2909548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.